Candriam S.C.A. Decreases Stock Position in Arvinas, Inc. (NASDAQ:ARVN)

Candriam S.C.A. reduced its holdings in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 4.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 503,936 shares of the company's stock after selling 20,845 shares during the quarter. Candriam S.C.A. owned about 0.73% of Arvinas worth $9,660,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. Braidwell LP lifted its holdings in Arvinas by 148.3% in the third quarter. Braidwell LP now owns 1,284,472 shares of the company's stock valued at $31,637,000 after acquiring an additional 767,242 shares during the period. Baker BROS. Advisors LP acquired a new stake in shares of Arvinas in the third quarter valued at about $9,989,000. JPMorgan Chase & Co. boosted its holdings in Arvinas by 18.7% during the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company's stock worth $57,371,000 after buying an additional 367,343 shares in the last quarter. FMR LLC boosted its holdings in Arvinas by 7.6% during the third quarter. FMR LLC now owns 2,883,604 shares of the company's stock worth $71,023,000 after buying an additional 204,317 shares in the last quarter. Finally, Wasatch Advisors LP grew its position in Arvinas by 58.3% during the third quarter. Wasatch Advisors LP now owns 435,943 shares of the company's stock worth $10,737,000 after buying an additional 160,510 shares during the period. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Arvinas

In related news, CEO John G. Houston sold 31,338 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. The trade was a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ian Taylor sold 9,020 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.71, for a total value of $150,724.20. Following the sale, the insider now owns 159,121 shares of the company's stock, valued at $2,658,911.91. This represents a 5.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 41,572 shares of company stock worth $695,030 in the last 90 days. 5.23% of the stock is owned by company insiders.

Remove Ads

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ARVN shares. Guggenheim reissued a "buy" rating and set a $57.00 price target on shares of Arvinas in a research note on Wednesday, February 12th. HC Wainwright reiterated a "buy" rating and set a $81.00 target price on shares of Arvinas in a research report on Tuesday. BMO Capital Markets reissued an "outperform" rating and issued a $82.00 target price (down previously from $88.00) on shares of Arvinas in a report on Wednesday, February 12th. Citigroup cut their price target on Arvinas from $28.00 to $19.00 and set a "neutral" rating for the company in a research note on Friday. Finally, BTIG Research assumed coverage on shares of Arvinas in a research note on Tuesday, December 10th. They issued a "buy" rating and a $69.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $56.08.

Arvinas Price Performance

ARVN stock traded down $9.26 during midday trading on Tuesday, hitting $8.30. The stock had a trading volume of 18,990,590 shares, compared to its average volume of 1,464,024. The company's 50-day moving average price is $18.19 and its 200 day moving average price is $22.33. The firm has a market cap of $570.81 million, a PE ratio of -3.00 and a beta of 1.95. Arvinas, Inc. has a 12-month low of $7.91 and a 12-month high of $46.62.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the prior year, the company earned ($2.53) earnings per share. As a group, sell-side analysts anticipate that Arvinas, Inc. will post -3.81 EPS for the current year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.